Research at Oslo University Hospital basis for international drug development initiative between Norway and India
SERCA Pharmaceuticals AS, a company established by Inven2 AS in October, recently entered a co-development agreement with Cadila Pharmaceuticals - an FDA-approved Indian Pharma company with some 6000 employees. SERCA Pharmaceuticals AS is established based on a drug development and innovation project on ischemia reperfusion injury in myocardial infarction that has been going on in the groups of Professors Kjetil Tasken (formerly NCMM UiO/OUH, now ICR, OUH) and Ivar Sjaastad (IEMF, OUH). The researchers have taken this forward to a drug candidate and have documented effects biochemically, in heart cells, by electrophysiology, on normal rat hearts and in rats with ischemia reperfusion injury where there is a cardioprotective effect.
The work has involved Birgitte Lygren (former postdoc), Ellen Østensen (PhD 2016), Ana Calejo (former postdoc and now researcher with UiO SPARK grant) in the Taskén group at UiO/OUH and has been done in collaboration with Professor Jo Klaveness at Institute of Pharmacy and Professor Ivar Sjaastad and Researcher Jan Magnus Aaronsen at Institute of Experimental Medical Research at Oslo University Hospital and in collaboration with Inven2, particularly Mohammed Amarzguioui and Kristin Sandereid, that have been involved in the technology and business development and led to the establishment of SERCA Pharmaceuticals AS.
SERCA Pharmaceuticals AS has won a 5-mill NOK Forny grant from RCN. The agreement with Cadila will take the project forward and provides a real chance to go into humans with planned phase 1 and 2 studies.
Inven2's most recent startup company, Serca Pharmaceuticals, signed a development agreement with Cadila Pharmaceuticals in New Delhi today. The signing was overseen by Prime Minister of Norway, Erna Solberg, during her official visit to India. Serca Pharmaceuticals is based on breakthrough science from Kjetil Taskéns Group at the University of Oslo. Read more
From major journals, first or last author from the Institute for Cancer Research
Kyte JA, Fåne A, Pule M, Gaudernack G(2019) Transient redirection of T cells for adoptive cell therapy with telomerase-specific T helper cell receptors isolated from long term survivors after cancer vaccination Oncoimmunology, 8(4), e1565236 DOI 10.1080/2162402X.2019.1565236, PubMed 30906659
Hauge A, Gaustad JV, Huang R, Simonsen TG, Wegner CS, Andersen LMK, Rofstad EK(2019) DCE-MRI and Quantitative Histology Reveal Enhanced Vessel Maturation but Impaired Perfusion and Increased Hypoxia in Bevacizumab-Treated Cervical Carcinoma Int J Radiat Oncol Biol Phys(in press) DOI 10.1016/j.ijrobp.2019.03.002, PubMed 30858145
Öjlert ÅK, Halvorsen AR, Nebdal D, Lund-Iversen M, Solberg S, Brustugun OT, Lingjaerde OC, Helland Å(2019) The immune microenvironment in non-small cell lung cancer is predictive of prognosis after surgery Mol Oncol(in press) DOI 10.1002/1878-0261.12475, PubMed 30854794
Brynildsen J, Petäjä L, Myhre PL, Lyngbakken MN, Nygård S, Stridsberg M, Christensen G, Ottesen AH, Pettilä V, Omland T, Røsjø H(2019) Circulating Secretoneurin Concentrations After Cardiac Surgery: Data From the FINNish Acute Kidney Injury Heart Study Crit Care Med, 47(5), e412-e419 DOI 10.1097/CCM.0000000000003670, PubMed 30730440
Köksal H, Dillard P, Josefsson SE, Maggadottir SM, Pollmann S, Fåne A, Blaker YN, Beiske K, Huse K, Kolstad A, Holte H, Kvalheim G, Smeland EB, Myklebust JH, Inderberg EM, Wälchli S(2019) Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma Blood Adv, 3(8), 1230-1243 DOI 10.1182/bloodadvances.2018029678, PubMed 30979721
Mukhopadhyay UK, Oturkar CC, Adams C, Wickramasekera N, Bansal S, Medisetty R, Miller A, Swetzig WM, Silwal-Pandit L, Borresen-Dale AL, Creighton CJ, Park JH, Konduri SD, Mukhopadhyay A, Caradori A, Omilian A, Bshara W, Kaipparettu BA, Das GM(2019) TP53 Status as a Determinant of Pro- versus Anti-tumorigenic Effects of Estrogen Receptor-beta in Breast Cancer J Natl Cancer Inst(in press) DOI 10.1093/jnci/djz051, PubMed 30990221